Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia, B-cell lymphoma, non-Hodgkin lymphoma and multiple myeloma. Despite reporting high response rates, the use of CAR-T therapy is associated with a number of practical challenges, including treatment-related adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as high costs and manufacturing difficulties. It is thus crucial to reduce the incidence and optimize the management of toxicities through careful patient selection and monitoring. CAR-T therapy is also being explored as a treatment option for chronic lymphocytic leukemia (CLL), where attempts with CAR-T have been unsuccessful due to CLL-induced T-cell dysfunction, a process that is currently not well understood.
In this podcast, Arnon Nagler, MD, MSc, of the Chaim Sheba Medical Center, Tel-Hashomer, Israel, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, Christian Chabannon, MD, PhD, of the Institut Paoli Calmettes, Marseille, France, and Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discuss key considerations for the use of CAR-T therapy in clinical practice, as presented at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH) 2021.
Hemophilia: the current standard of care and the value of novel gene therapies
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The current role of stem cell transplantation in MPNs & how this may change with novel agents
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Insights into the changing role of chemotherapy in lymphoma
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive